Zealand Pharma appoints Ivan Møller as new SVP, Technical Development & Operations
19 January 2018 -

Biotechnology company Zealand Pharma A/S (CPH:ZEAL)(NYSE:ZEAL) on Friday announced that it has appointed Ivan Møller to the new position of senior vice president, Technical Development & Operations, effective 1 March 2018.

Most recently, Møller held senior management positions at Novartis in both generics and pharmaceutical manufacturing, as well as strategy, quality assurance, contract manufacturing and supply chain leadership in Germany, the US and Switzerland.

Prior to joining Novartis, Møller was project leader at The Boston Consulting Group in New York, NY where he led client engagements in the pharmaceutical R&D and manufacturing areas. He started his career at PolyPeptide Laboratories where he was head of Production site.

Zealand Pharma is focused on the discovery, design and development of innovative peptide-based medicines. It has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, as well as a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.